Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
567.74
+7.98 (1.43%)
At close: Jul 11, 2025, 4:00 PM
567.06
-0.68 (-0.12%)
After-hours: Jul 11, 2025, 6:10 PM EDT
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$932,457
Profits / Employee
$297,849
Market Cap
59.99B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
REGN News
- 2 days ago - Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025 - Seeking Alpha
- 10 days ago - Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - WSJ
- 10 days ago - US FDA approves Regeneron's blood cancer therapy - Reuters
- 15 days ago - Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 - GlobeNewsWire
- 17 days ago - Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade - Seeking Alpha
- 18 days ago - Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization - GlobeNewsWire
- 22 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 22 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire